论文部分内容阅读
目的探讨血清前列腺特异性抗原(PSA)与前列腺癌病理分级、临床分期之间的关系。方法经病理检查确诊为前列腺癌的患者41例,在有创检查前或检查后1周或手术前抽取静脉血检测血清PSA。依据苏木素-伊红染色切片中肿瘤的组织学形态,结合临床相关资料分别进行病理分级、临床分期。采用Spearman等级相关分析等统计学方法分析血清PSA和前列腺癌的病理分级、临床分期的关系。结果不同病理分级血清PSA升高比例及血清PSA值差异均无统计学意义(P均>0.05);不同临床分期血清PSA升高比例差异无统计学意义(P>0.05),血清PSA值差异有统计学意义(P<0.05);血清PSA值与前列腺癌的病理分级、临床分期均呈正相关(r=0.362,P<0.05;r=0.478,P<0.05)。结论血清PSA不仅是前列腺癌的一个有力的筛选和诊断指标,而且可能是前列腺癌患者治疗方案选择和判断预后的一个有意义的指标。
Objective To investigate the relationship between serum prostate specific antigen (PSA) and the pathological grade and clinical stage of prostate cancer. Methods Totally 41 patients diagnosed as prostate cancer by pathology were enrolled in this study. Serum PSA was measured before or after invasive surgery or 1 week before or after surgery. According to the histological morphology of the tumor in hematoxylin-eosin-stained sections, pathological grade and clinical stage were respectively combined with clinical data. Spearman rank correlation analysis and other statistical methods to analyze the relationship between serum PSA and the pathological grade and clinical stage of prostate cancer. Results There was no significant difference in the proportion of serum PSA and serum PSA between different pathological grades (all P> 0.05). There was no significant difference in PSA between different clinical stages (P> 0.05) (P <0.05). The serum PSA level was positively correlated with the pathological grade and clinical stage of prostate cancer (r = 0.362, P <0.05; r = 0.478, P <0.05). Conclusions Serum PSA is not only a powerful index for screening and diagnosis of prostate cancer, but also may be a meaningful indicator of treatment options and prognosis in patients with prostate cancer.